| Literature DB >> 15817124 |
Samuel Wanji1, Nicholas Tendongfor, Mathias Esum, Siker Sj Yundze, Mark J Taylor, Peter Enyong.
Abstract
BACKGROUND: Individuals with high microfilarial loads of Loa loa are at increased risk of neurologic serious adverse (SAE) events following ivermectin treatment against onchocerciasis. RAPLOA (Rapid Assessment Procedure for loiasis), a newly developed rapid assessment procedure for loiasis that relates the prevalence of key clinical manifestation of loiasis (history of eye worm) to the level of endemicity of the infection (prevalence of high intensity), is a very useful tool to identify areas at potential risk of L. loa post ivermectin treatment encephalopathy. In a perspective of treatment decision making in areas of co-endemicity of loiasis/onchocerciasis, it would be advantageous (both in time and cost savings) for national onchocerciasis control programmes to use RAPLOA and the Rapid epidemiologic assessment for onchocerciasis (REA), in combination in given surveys. Since each of the two rapid assessment tools have their own specificities, the workability of combining the two methods needed to be tested.Entities:
Year: 2005 PMID: 15817124 PMCID: PMC1090603 DOI: 10.1186/1475-2883-4-2
Source DB: PubMed Journal: Filaria J ISSN: 1475-2883
Figure 1Map of the Widikum area showing the geographical location of the villages surveyed.
Prevalence and intensity (mf/ml) of L. loa determined by RAPLOA and by the Thick blood film techniques.
| Prevalence (%) | Intensity (mf/ml) | |||||||
| Village | Population* | No. Examined | RAPLOA | Thick blood film | Arithmetic Mean Mf +ve & -ve individuals | Arithmetic Mean Mf +ve individuals | William's means > 15 | William's means > 20 (CMFL) |
| 250 | 49 | 24.49 | 6.12 | 1.63 | 27.67 | 1.22 | 1.25 | |
| 1889 | 141 | 21.99 | 3.55 | 81.99 | 2313 | 1.25 | 1.30 | |
| 65 | 21 | 19.05 | 14.29 | 86.67 | 608.67 | 2.36 | 2.21 | |
| 516 | 159 | 30.82 | 10.69 | 1.3.77 | 970.79 | 1.83 | 2.02 | |
| 260 | 120 | 13.33 | 3.36 | 8.00 | 240.00 | 1.18 | 1.14 | |
| 1079 | 96 | 14.58 | 9.38 | 418.96 | 4468.89 | 1.87 | 1.96 | |
| 765 | 138 | 16.67 | 7.25 | 232.46 | 3208.00 | 1.53 | 1.55 | |
| 83 | 32 | 9.38 | 12.50 | 293.13 | 2345.00 | 2.08 | 2.13 | |
| 77 | 29 | 31.03 | 10.34 | 13.10 | 126.67 | 1.609 | 1.93 | |
| 707 | 192 | 20.31 | 4.69 | 119.27 | 2544.44 | 1.39 | 1.40 | |
* Total population recorded during a census conducted in study villages; CMFL: Community microfilarial load. Mf +ve: Microfilaraemic, MF -ve: amicrofilaraemic
Prevalence and Intensity of O. volvulus determined by REA and Skin snip
| Prevalence (%) | Intensity (mf/Skin snip) | |||||||
| Village | Population* | No. Examined | REA | Skin snip | Arithmetic Mean Mf +ve & -ve individuals | Arithmetic Mean Mf +ve individuals | William's means ≥ 15 | William's means ≥ 20 (CMFL) |
| 250 | 49 | 40.82 | 69.39 | 14.57 | 21.00 | 5.07 | 4.76 | |
| 1889 | 141 | 38.30 | 66.67 | 12.54 | 18.80 | 4.06 | 4.19 | |
| 65 | 21 | 23.81 | 95.24 | 65.26 | 68.52 | 13.38 | 14.60 | |
| 516 | 159 | 54.72 | 94.34 | 32.45 | 34.40 | 17.31 | 18.58 | |
| 260 | 120 | 65.00 | 85.83 | 19.70 | 22.95 | 7.76 | 7.82 | |
| 1079 | 96 | 20.83 | 72.92 | 14.13 | 19.37 | 5.24 | 5.69 | |
| 765 | 138 | 56.52 | 76.09 | 18.45 | 24.25 | 6.85 | 7.70 | |
| 83 | 32 | 21.88 | 87.50 | 11.25 | 12.86 | 5.41 | 6.52 | |
| 77 | 29 | 55.17 | 86.21 | 28.07 | 32.56 | 10.53 | 10.49 | |
| 707 | 192 | 39.06 | 86.46 | 31.68 | 36.43 | 10.57 | 10.89 | |
* Total population recorded during a census conducted in study villages, CMFL : Community microfilarial load ; Mf +ve: Microfiladermic, MF -ve: amicrofiladermic individuals & -ve
Figure 2a: Relationship between the RAPLOA and L. loa microfilaraemia prevalences. Dotted lines represent the thresholds levels above which there is increased risk of neurologic SAEs. b Relationship between the REA and the microfiladermia prevalences. Dotted lines represent the thresholds levels above which mass treatment with ivermectin is most urgent (microfiladermia) or highly desirable (REA). c Relationship between RAPLOA and REA prevalences. A: Large-scale treatment with low risk of neurologic SAEs; B: Large scale treatment with high risk of neurologic SAEs; C: No large-scale treatment with ivermectin D: No large-scale treatment with ivermectin. Dotted lines represent the thresholds levels above which the risk of neurologic SAEs is high
Figure 3Relationship between RAPLOA prevalence and Loa microfilaraemia: (▲) New data, (o) Data generated during RAPLOA development.